Drug Trial Radar · NCT05957471
Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
27
Planned (sponsor's estimate)
Start
Jun 26, 2023
Primary completion
Jun 2025
Study completion Jun 2025
Sponsor
- Lead sponsor
- Biocity Biopharmaceutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Patients with Locally Advanced or Metastatic Solid Tumors.
Conditions
- Locally Advanced or Metastatic Solid Tumors
Interventions
Drug: BC3195 for InjectionDrug
BC3195 via intravenous(IV).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLTs) .Time frame: Dose limiting toxicities (DLT) will be assessed At the end of Cycle 1 (each cycle is 21 days).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.